Trials / Completed
CompletedNCT05278663
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Patients
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the safety and tolerability of multiple oral doses of E6742 in participants with systemic lupus erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E6742 | E6742 tablet. |
| OTHER | Placebo | E6742-matching placebo tablet. |
Timeline
- Start date
- 2022-04-14
- Primary completion
- 2023-09-04
- Completion
- 2023-09-04
- First posted
- 2022-03-14
- Last updated
- 2023-09-29
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05278663. Inclusion in this directory is not an endorsement.